

Article title: An exploratory study of the effect of metformin on the whole blood transcriptome of nondiabetic older adults with age-related macular degeneration

Journal name: GeroScience

Authors: Xinyi Chen, MD,^{1,2} Yi Stephanie Zhang, MD,^{1,2} Daisy Yan, MPH,² Thuy Doan, MD,^{1,2} Liangbo Linus Shen, MD,^{1,3} Abu Tahir Taha, MD,^{1,5} Daphne Yang, BA,¹ Catherine Psaras, PhD,¹ Jacquelyn K. Callander, MD,¹ Nicole Y. Xin, BA,¹ Arjun Shivkumar, BA,¹ Amani A. Fawzi, MD,⁴ Glenn Yiu, MD, PhD,⁵ David G. Telander, MD, PhD,⁶ Loh-Shan Bryan Leung, MD,⁷ Christina Flaxel, MD,⁸ John C. Newman, MD,^{9,10} Jeremy D. Keenan, MD,^{1,2} Jay M. Stewart, MD¹

¹ University of California, San Francisco, Department of Ophthalmology, San Francisco, California, USA.

² University of California, San Francisco, Francis I. Proctor Foundation for Research in Ophthalmology, San Francisco, California, USA.

³ Duke University School of Medicine, Department of Ophthalmology, Durham, NC, United States

⁴ Northwestern University, Feinberg School of Medicine, Department of Ophthalmology, Chicago, Illinois, USA.

⁵ University of California, Davis, Department of Ophthalmology & Visual Sciences, Sacramento, California, USA.

⁶ Retinal Consultants Medical Group, Sacramento, California, USA.

⁷ Stanford University School of Medicine, Department of Ophthalmology, Palo Alto, California, USA.

⁸ Oregon Health & Science University, Department of Ophthalmology, Casey Eye Institute, Portland, Oregon, USA.

⁹ Buck Institute for Research on Aging, Novato, California, USA.

¹⁰ University of California, San Francisco, Division of Geriatrics, San Francisco, California, USA.

Corresponding author: Jay M. Stewart, jay.stewart@ucsf.edu

Supplementary Table 1. Comparison of demographic and other characteristics between trial patients who consented to blood draw and those who did not undergo blood draw.

	Blood draw group (N=15)	No blood draw group (N=51)	P-value
Age (years), mean $\pm$ SD	77.8 $\pm$ 7.2	78.0 $\pm$ 15.2	0.364
Sex, n (%)			
Male	5 (33.3)	25 (37.9)	0.560
Race & ethnicity, n (%)			
White*	13 (86.7)	50 (75.8)	0.165
Asian, Native Hawaiian & other Pacific Islander*	1 (6.7)	2 (3.0)	
Hispanic	1 (6.7)	2 (3.0)	
Smoking history, n (%)			
Yes	5 (33.3)	28 (42.4)	0.385
BMI, mean $\pm$ SD	26.8 $\pm$ 6.0	27.0 $\pm$ 5.3	0.972
BCVA[†] at baseline (letters), mean $\pm$ SD	52 $\pm$ 16	45 $\pm$ 22	0.320
BCVA[†] at 18 months (letters), mean $\pm$ SD	46 $\pm$ 18	46 $\pm$ 18	0.851
LLVA[‡] at baseline (letters), mean $\pm$ SD	35 $\pm$ 11	34 $\pm$ 15	0.765
LLVA[‡] at 18 months (letters), mean $\pm$ SD	29 $\pm$ 15	34 $\pm$ 17	0.288
Multifocal lesion, n (%)			
Yes	12 (80.0)	36 (72.0)	0.741
Foveal center point involvement, n (%)			
Yes	13 (86.7)	47 (94.0)	0.325
GA area at baseline, mm², mean $\pm$ SD	7.2 $\pm$ 5.1	9.0 $\pm$ 6.1	0.388
GA area at 18 months, mm², mean $\pm$ SD	11.1 $\pm$ 7.0	11.9 $\pm$ 8.5	0.754

Note. SD: standard deviation; BMI: body mass index; GA: geographic atrophy.

*: Non-Hispanic

[†]: Best-Corrected Visual Acuity using the ETDRS chart. BCVA of the worse eye was included in the analysis.

[‡]: Low luminance visual acuity using a 2.0 log unit neutral density filter. LLVA of the worse eye was included in the analysis.